Multicancer Early Detection Technologies: A Review Informed by Past Cancer Screening Studies

Area of Science:

• Oncology
• Medical Screening
• Biomarker Discovery

Background:

• Over 75% of cancer deaths stem from cancers without effective screening methods.
• Liquid biopsies represent a potential solution to address these screening gaps.
• Assessing the clinical benefit of novel screening approaches remains critical.

Purpose of the Study:

• To review past cancer screening trials (ovarian, prostate, pancreatic, esophageal) to inform future research.
• To identify challenges and propose solutions for evaluating new cancer screening technologies.
• To leverage multicancer early detection tests for improved trial designs.

Main Methods:

• Analysis of historical randomized controlled trials (RCTs) for cancer screening.
• Evaluation of limitations including small effect sizes, study duration, and confounding factors.
• Proposal of alternative trial designs using surrogate endpoints and high-risk populations.

Main Results:

• Traditional RCTs for mortality reduction require extensive resources (millions of screening-years, decades).
• Past trials faced limitations due to disease characteristics and study design.
• Future trials could benefit from surrogate endpoints like late-stage incidence.

Conclusions:

• Innovative trial designs, including those using surrogate endpoints, are essential for efficient evaluation of new cancer screening methods.
• Conditional approvals coupled with real-world evidence generation can accelerate progress.
• Multicancer early detection tests offer opportunities to advance practical study designs for cancer screening.